Νέα

Ferring’s European Marketing Authorisation Application for controlled release misoprostol vaginal delivery system for the induction of labour accepted for review

Saint-Prex, Switzerland, 5 November 2012 – Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation Application (MAA) for its controlled release, removable misoprostol vaginal delivery system (MVDS) has been accepted for review under the decentralised procedure. Ferring is seeking approval for the MVDS for induction of labour .. read more

05
Nov
Ανήκει στην Κατηγορία: Νέα